How many units of bpc-157 daily? what the record shows

Last updated 2026-07-23

how many units of bpc-157 should you inject daily?

The honest answer is that nobody can give you a validated number, because BPC-157 has no FDA-approved human dosing protocol. It is not an approved drug product in the Drugs@FDA database ^[1], and it does not appear on either the 503A or 503B bulk drug substance lists that let compounding pharmacies use a raw ingredient in human prescriptions ^[2][3]. What you'll find online, on forums and vendor sites, are "unit" conventions borrowed from insulin syringe markings (a standard U-100 syringe has 100 units per mL). Those numbers describe how people are drawing up a reconstituted vial, not a dose validated in a human trial. The few human studies that exist used specific, small-sample protocols set by researchers or clinicians, not a self-selected daily unit count. The practical reality: if you're getting BPC-157 through a legitimate route, a licensed prescriber and pharmacy determine the dose, the frequency, and the syringe markings for you. Nobody should be reverse-engineering a dose from a Reddit thread and a bathroom scale.

what does "units" even mean for a peptide like this?

"Units" is a syringe-volume convention, not a scientific dosing unit. Insulin syringes are marked in units because insulin has historically been dosed that way, and people repurposing those syringes for peptide reconstitution borrowed the same marks. One unit on a U-100 syringe equals 0.01 mL. What that unit corresponds to in micrograms of actual peptide depends entirely on how much BPC-157 powder was dissolved in how much liquid, meaning the same "20 units" could be a wildly different dose from one vial to the next. This is exactly why unit-based dosing floating around online is not a substitute for a real prescription. A pharmacy-dispensed product comes with a known concentration and a specific volume instruction tied to a specific patient's prescription, not a generic unit count meant to apply to everyone.

what doses have actually been tested, and in what species?

This is the part that gets glossed over constantly: the large majority of BPC-157 dosing data comes from rodent studies, not humans. Doses in that literature are typically reported in micrograms per kilogram of body weight, given to rats or mice, often by injection or in drinking water. A 2018 review in Current Pharmaceutical Design covering BPC-157's effects alongside standard angiogenic growth factors on gastrointestinal and musculoskeletal tissue healing draws its dosing data from these animal models ^[4], and a 2019 review in Cell and Tissue Research on BPC-157 accelerating musculoskeletal soft tissue healing is explicit that the mechanistic and dosing story is built from animal work ^[5]. A microgram-per-kilogram number from a rat study cannot be scaled to a human dose by simple arithmetic. Rodent metabolism, injection route, and tissue targets differ enough from humans that pharmacologists don't consider that kind of conversion valid without actual human pharmacokinetic study, which for BPC-157 largely doesn't exist yet. A 2025 literature and patent review in Pharmaceuticals looked at BPC-157's proposed mechanisms and patent landscape and reinforces that most of the supporting data is preclinical ^[6]. So when you see a specific microgram figure attached to a rat study cited as though it applies to you, that's a red flag for the source, not a shortcut you should take.

has BPC-157 dosing actually been tested in humans?

A little, and only in small, specific clinical contexts, not as a general daily supplement protocol. A 2021 study in Alternative Therapies in Health and Medicine looked at intra-articular BPC-157 injection for multiple types of knee pain ^[7], and a 2024 pilot study in the same journal examined BPC-157's effect on symptoms in patients with interstitial cystitis ^[8]. Both are small, early studies testing a specific injection protocol for a specific condition, not open-ended daily-dosing research. These studies matter because they're some of the only human data that exists, but they don't establish a general "daily units" answer. A protocol used in a knee injection trial doesn't tell you anything about a subcutaneous daily-dose regimen for tendon recovery, and a bladder-focused pilot study doesn't generalize to gut health use. Each study answers its own narrow question, and that's it. A 2025 systematic review in HSS Journal specifically covering BPC-157's emerging use in orthopaedic sports medicine catalogs what human and animal evidence exists across musculoskeletal applications, and the picture is still mostly preclinical with limited clinical follow-through ^[9]. If you want the fuller research landscape rather than the dosing question alone, our BPC-157 peptide overview walks through what these studies actually found.

why do different sellers list different daily unit ranges?

Because there's no regulatory anchor forcing consistency. When a drug is FDA-approved, its label specifies an exact dose range backed by clinical trial data, reviewed by FDA, and codified. BPC-157 has none of that. It's not in the Drugs@FDA database ^[1], and FDA's own bulk drug substances page for 503A compounding explains the process by which a substance can be nominated and evaluated, which BPC-157 has not cleared ^[10]. The bulk substance lists under 21 CFR 216.23 (503A) ^[2] and 21 CFR 216.24 (503B) ^[3] are the actual regulatory gatekeepers, and BPC-157 is absent from both as an approved bulk ingredient for compounding. Without that anchor, every seller is free to publish whatever unit range sounds plausible, often copied from other vendor sites, forum consensus, or extrapolated (badly) from rat studies. That's how you end up with wildly different "recommended daily unit" numbers across five different websites, none of them citing an actual human trial for the number. Our BPC-157 dosage page goes deeper into how these vendor numbers get generated and why they shouldn't be treated as clinical guidance.

does the injection route change how many units you'd use?

Route matters a lot in the animal literature, and there's no reason to think it wouldn't matter in humans, though that hasn't been tested directly. A 2021 review in Frontiers in Pharmacology on BPC-157 and wound healing discusses systemic versus local administration effects in animal models ^[11], and separate work on BPC-157's relationship to blood vessel formation, published in Current Pharmaceutical Design in 2014, focuses specifically on how the peptide appears to affect angiogenesis based on animal data ^[12]. Subcutaneous injection, intramuscular injection, oral administration, and localized intra-articular injection are not interchangeable in terms of how much reaches target tissue or how fast. The 2021 knee pain study specifically used intra-articular injection ^[7], a route chosen for a joint-specific condition, which is a different delivery question than a subcutaneous daily-dose regimen aimed at systemic soft tissue recovery. If you're comparing information about BPC-157 peptide injections, pay attention to whether the source is talking about the same route, because dose and route are not separable variables.

is there a difference between dosing for tendon recovery vs gut health vs performance use?

The underlying animal literature covers tendon, ligament, muscle, and bone healing mechanisms distinctly, and the proposed dosing (in animal studies) differs by what's being studied. A 2011 study in the Journal of Applied Physiology specifically examined how BPC-157 affects tendon outgrowth, cell survival, and cell migration in tendon explant and animal models, a mechanistic tendon-specific investigation ^[13]. That is a different research question, with different concentrations tested, than a gut-focused study or a systemic performance claim. Vendors marketing BPC-157 for "gut health" often cite the peptide's original discovery context (it was isolated from gastric juice) but layer performance and injury-recovery dosing suggestions on top without distinguishing the underlying study population, species, or endpoint. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled bluntly "Regeneration or Risk?", takes a critical look at the musculoskeletal healing claims specifically and flags where the evidence is thinner than marketing suggests ^[14]. That kind of skepticism is worth carrying into any dosing claim you see online, whatever the stated use case.

what do orthopaedic and sports medicine reviews say about BPC-157 dosing right now?

The clinical field itself is cautious, and recent reviews say so directly. A 2026 piece in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covering therapeutic peptides in orthopaedics discusses BPC-157 among other investigational peptides and addresses the challenges practitioners face given the absence of approved dosing standards ^[15]. A companion 2026 primer in The American Journal of Sports Medicine, aimed specifically at orthopaedic and sports medicine physicians using injectable peptide therapy, frames BPC-157 as a substance requiring caution given the state of the evidence ^[16]. A 2025 review in Arthroscopy looking at injectable therapeutic peptides as a potential adjunct to regenerative medicine and sports performance likewise treats BPC-157 dosing as an open question rather than a settled protocol ^[17]. And a 2026 paper in Sports Medicine covering the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance places BPC-157 squarely in the "unapproved" category needing more rigorous human study before dosing guidance can be trusted ^[18]. The consistent theme across all of these 2025 and 2026 reviews: clinicians researching BPC-157 are not handing out a settled daily unit count either. They're describing an evidence gap, not a protocol.

what happens if you just guess at a daily unit number?

You're accepting real, unquantified risk with no dosing data to catch you if something goes wrong. Because BPC-157 isn't FDA-approved ^[1] and isn't on the compounding bulk lists ^[2][3], there's no clinical trial safety monitoring behind whatever number you pick. Nobody has run the equivalent of a Phase I dose-escalation study in humans to establish a maximum tolerated dose, a minimum effective dose, or even reliable pharmacokinetics for a given route. Guessing based on a forum thread means you don't know if you're under-dosing (wasting money, seeing nothing) or over-dosing (unknown territory, since even the animal studies don't map cleanly to a safe human ceiling). For a rundown of what side effects and risks have actually been reported or theorized, see our BPC-157 peptide side effects page. It's a much better use of your research time than trying to average five vendor unit charts.

how does a compounding pharmacy actually determine the dose?

When BPC-157 is provider-reviewed and dispensed through a licensed compounding pharmacy, the dose isn't picked by the patient or by marketing copy. It's set based on the concentration of the compounded preparation, the prescriber's clinical judgment for that specific patient and condition, and the pharmacy's compounding standards under the framework set out in 21 U.S.C. 353a, the federal statute governing pharmacy compounding ^[19]. That statute is explicit that compounded preparations require a valid prescription for an identified patient, based on a documented clinical need, which is a different world from a self-selected daily unit count copied off a website. BPC-157 Co works with a licensed compounding pharmacy partner to fulfill provider-reviewed orders; BPC-157 Co itself does not compound anything. If a prescriber determines BPC-157 is appropriate for you, the dispensing pharmacy's label tells you the actual concentration and the actual volume or unit count to draw, calculated for your specific prescription rather than a generic online chart. If you want a sense of how dosing gets calculated more broadly, including the syringe math, our BPC-157 dosage calculator walks through the concentration-and-volume logic, though it's educational, not a replacement for a prescriber's instruction.

where should you go from here if you're considering BPC-157?

Start by being honest with yourself about what evidence tier you're standing on. The mechanistic and dosing literature is overwhelmingly rodent-based ^[4][5][6], the human data is small and narrow (a knee pain study ^[7], an interstitial cystitis pilot ^[8]), and the 2025-2026 orthopaedic and sports medicine reviews all flag the same gap between preclinical promise and validated human protocol ^{[9][14][15][16][17][18]}. If you're going to pursue this at all, the sourcing question matters as much as the dosing question. Products purchased as "research chemicals" outside a pharmacy relationship carry no concentration guarantee, no prescriber oversight, and no accountability if the vial isn't what the label claims. For a look at how legitimate sourcing works versus the research-chemical gray market, see BPC-157 for sale. And if you're at the point of actually wanting a provider-reviewed path, that means talking to a prescriber first, not picking a unit number off a chart.

Frequently asked questions

how many units of bpc-157 should i take per day?

There's no FDA-approved or clinically validated daily unit count for BPC-157. Unit-based numbers circulating online come from vendor convention and forum consensus, not human trials. If a prescriber determines BPC-157 is appropriate for you, dosing is set by the prescription and the compounding pharmacy's concentration, not a generic chart.

is bpc-157 dosing based on human studies or animal studies?

Overwhelmingly animal studies. Most published BPC-157 dosing data comes from rodent research measured in micrograms per kilogram of body weight ^[4][5]. Human data exists but is limited to small, specific trials like a knee pain injection study (n small, 2021) ^[7] and an interstitial cystitis pilot study (2024) ^[8], neither of which establishes a general daily dose.

what does a 'unit' mean when people talk about bpc-157 injections?

A unit refers to the markings on a U-100 insulin syringe, where 100 units equals 1 mL. It's a volume measurement borrowed for peptide reconstitution, not a standardized dose. The actual amount of peptide per unit depends entirely on how concentrated the reconstituted vial is, which varies by preparation.

can i convert a rat study dose into a human daily unit number?

No, not reliably. Rodent doses reported in micrograms per kilogram don't translate to human doses through simple scaling, because metabolism, injection route, and tissue response differ between species. Reviews covering BPC-157's mechanism data are explicit that this is preclinical, animal-derived information ^[4][6], not a basis for human dose conversion.

why do bpc-157 vendors list different daily dosing ranges?

Because there's no FDA-approved label or bulk compounding listing to anchor a consistent number. BPC-157 isn't in the Drugs@FDA database ^[1] and isn't on the 503A ^[2] or 503B ^[3] bulk substance lists, so vendors have no regulatory dosing standard to cite and often copy numbers from each other or from animal studies.

is bpc-157 fda approved for any condition or dose?

No. BPC-157 does not appear as an approved drug product in the Drugs@FDA database ^[1], and it isn't on the FDA's current bulk drug substance lists for 503A or 503B compounding ^[2][3]. There is no FDA-sanctioned dose, indication, or daily unit protocol for it.

does the injection route affect how much bpc-157 to use?

Route appears to matter based on animal research into local versus systemic administration ^[11] and BPC-157's effects on blood vessel formation ^[12], but this hasn't been formally tested for dosing equivalence in humans. A knee study used intra-articular injection specifically ^[7], a different route and rationale than a general subcutaneous daily protocol.

has bpc-157 been tested for gut health dosing in humans?

Not directly in a published human trial we can point to. BPC-157 was originally isolated from gastric juice, and much of the gut-healing mechanism data comes from animal studies ^[4][5]. The human studies that exist focus on knee pain ^[7] and interstitial cystitis ^[8], not general gut health dosing.

what's the risk of guessing a daily unit dose without a prescriber?

You're operating with zero human safety data behind your specific number. There's no dose-escalation study establishing a maximum tolerated human dose or reliable pharmacokinetics for BPC-157. See our side effects overview for what's been reported or theorized, and consider that self-dosing removes any clinical oversight.

how does a compounding pharmacy decide the bpc-157 dose?

Compounding under 21 U.S.C. 353a requires a valid prescription for a named patient based on documented clinical need ^[19]. A licensed pharmacy sets the concentration of the preparation and the prescriber determines frequency and volume for that specific patient, which is different from a self-selected online unit count.

do recent orthopaedic reviews recommend a specific bpc-157 dose?

No. Recent 2025-2026 reviews in journals like The American Journal of Sports Medicine ^[16], Arthroscopy ^[17], and Sports Medicine ^[18] discuss BPC-157 as an investigational, unapproved peptide and describe dosing as an open research question, not a settled clinical protocol.

is bpc-157 dosing the same for tendon injury vs performance use?

The underlying animal research differs by target tissue; tendon-specific mechanistic work exists ^[13], separate from systemic or performance-oriented claims. No published research validates one daily unit number across tendon recovery, gut health, and performance use as though they're interchangeable indications.

Sources

1. FDA, Drugs@FDA database: BPC-157 is not listed as an FDA-approved drug product
2. eCFR, 21 CFR 216.23 (503A Bulks List): BPC-157 is absent from the FDA's 503A bulk drug substances list for compounding
3. eCFR, 21 CFR 216.24 (503B Bulks List): BPC-157 is absent from the FDA's 503B bulk drug substances list for outsourcing facility compounding
4. Current Pharmaceutical Design, 2018 (PMID 29998800): BPC-157 dosing and mechanism data on GI, tendon, ligament, muscle and bone healing is drawn from animal models
5. Cell and Tissue Research, 2019 (PMID 30915550): review of BPC-157's role in musculoskeletal soft tissue healing built on animal study evidence
6. Pharmaceuticals (Basel), 2025 (PMID 40005999): literature and patent review confirms most BPC-157 mechanistic evidence remains preclinical
7. Alternative Therapies in Health and Medicine, 2021 (PMID 34324435): small human study tested intra-articular BPC-157 injection for multiple types of knee pain
8. Alternative Therapies in Health and Medicine, 2024 (PMID 39325560): pilot study examined BPC-157's effect on symptoms in patients with interstitial cystitis
9. HSS Journal, 2025 (PMID 40756949): systematic review of BPC-157 use in orthopaedic sports medicine finds evidence still largely preclinical
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA describes the nomination and evaluation process for bulk substances used in 503A compounding
11. Frontiers in Pharmacology, 2021 (PMID 34267654): review discusses systemic versus local BPC-157 administration effects on wound healing in animal models
12. Current Pharmaceutical Design, 2014 (PMID 23782145): BPC-157's effects on blood vessel formation studied in animal models
13. Journal of Applied Physiology, 2011 (PMID 21030672): study examined how BPC-157 affects tendon outgrowth, cell survival and cell migration in tendon models
14. Current Reviews in Musculoskeletal Medicine, 2025 (PMID 40789979): narrative review critically examines BPC-157 musculoskeletal healing claims against the underlying evidence
15. JAAOS Global Research & Reviews, 2026 (PMID 41490200): review discusses challenges of using investigational peptides like BPC-157 in orthopaedics given lack of approved dosing standards
16. American Journal of Sports Medicine, 2026 (PMID 41476424): primer for orthopaedic and sports medicine physicians frames BPC-157 as requiring caution given the state of dosing evidence
17. Arthroscopy, 2025 (PMID 39265666): review of injectable therapeutic peptides treats BPC-157 dosing as an open question rather than settled protocol
18. Sports Medicine, 2026 (PMID 41966639): review classifies BPC-157 among unapproved peptide therapies needing more rigorous human study before dosing guidance is established
19. Cornell Law School LII, 21 U.S.C. 353a: federal statute requires compounded preparations to be based on a valid prescription for an identified patient